// App-Quantinova.ai

4034 : Activity of Single Agent Drugs in Phase I and II Trials Best Predicts Future Clinical Utility in Multiple Myeloma

Researchers

Presenter

  • Steven R Schuster

Principal Investigators

  • Meaghan L. Khan

  • Kaitlyn E. Zidich

  • Victor H Jimenez-Zepeda

  • Rafael Fonseca

  • Keith Stewart

Medical Centers

  • Research, Mayo Clinic, Scottsdale, AZ

  • Hematology/Oncology, Princess MArgaret Hospital, Toronto, ON, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Arsenic trioxide

  • arsenic

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Bendamustine

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • Panobinostat

  • carfilzomib Intravenous

  • daratumumab Intravenous

  • Fotemustine

  • Thalidomide

  • Vincristine

  • Doxorubicin

  • Bortezomib

  • Elotuzumab

  • Idarubicin Hydrochloride

  • Paclitaxel

  • Perifosine

  • Prednisone

  • Siltuximab

  • Teniposide

  • Vorinostat

  • Interferon

  • Etoposide

  • Etoposide phosphate

  • Marizomib

  • Melphalan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved